Physician profile
Jonathan Cagle
NPI 1659963882
$1,464.18
in general payments reported to CMS, 2019-2025
14 companies · $507 in 2025
The $507 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $137 · 2023: $374 · 2024: $446 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,327.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $485.98 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $287.14 | 2023-2025 | |
| Lundbeck LLC | $219.98 | 2023-2025 | Rexulti, Vyepti |
| Lilly USA, LLC | $111.68 | 2023-2025 | Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $79.65 | 2024-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.68 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $41.83 | 2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Corium, LLC | $40.62 | 2025 | Azstarys |
| Idorsia Pharmaceuticals US INC | $33.26 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $27.89 | 2023-2024 | Nuedexta, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $23.41 | 2024 | Trintellix |
| Csl Behring | $22.54 | 2025 | Andembry |
| Indivior INC. | $17.25 | 2025 | Sublocade |
| Paratek Pharmaceuticals, INC. | $14.27 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Cagle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.